Prognostic parameters of luminal A and luminal B intrinsic
· Prognosis of breast cancer and success of therapeutic interventions largely rely on the clinico-pathologic and biological characteristics of the tumor and vary due to the heterogeneous nature of breast cancers. The aim of this study was to determine the frequency and prognostic parameters of luminal breast cancers in our population to devise targeted and personalized therapeutic regimens
Get Price
Efficacy of chemotherapy for lymph node-positive luminal A
· Luminal type A has better prognosis than other breast cancer subtypes. Oncologists define luminal A as estrogen receptor (ER) > 1 progesterone receptor (PR) ≥ 20 breast cancer with negative human epidermal growth factor receptor-2 (HER2) and Ki-67 < 14 of clinical cases 4 .
Get Price
Breast Cancer Cell Line Classification and Its Relevance
· Luminal breast cancer cell lines are characterized by positive ER and/or PR expression despite the existence of a few exceptional cases such as IBEP-1 and IBEP-3 where PR positivity drives their luminal phenotype. This type of cell lines exhibits high expression of a panel of luminal feature associated genes/proteins including e.g. ESR1
Get Price
Distinguishing Low-Risk Luminal A Breast Cancer Subtypes
· Low-risk luminal A subtype was defined as negative for both Ki-67 and p53 (luminal A ki-67- p53- ) and others subtypes were considered to be high-risk luminal A breast cancer. A cut-off value of 10 for p53 was a good predictor of clinical outcome in all patients and luminal A breast cancer patients.
Get PriceMolecular Subtypes of Breast CancerKomen
About 30-45 percent of breast cancers are luminal A tumors . Of the 4 major subtypes luminal A tumors tend to have the best prognosis with fairly high survival rates and fairly low recurrence rates . Luminal B. Luminal tumor cells look like those of breast cancers that start in the inner (luminal) cells lining the mammary ducts.
Get Price
The genetics of luminal A-like breast cancer (Zhang 2020)
· Luminal A-like is a subtype of breast cancer with the best prognosis and it accounts for 30-45 breast cancer cases. It is characterized by cancerous cells originating in the inner or luminal cells that line the mammary ducts. Moreover this breast cancer subtype is characterized by a cancerous growth in response to excess estrogen.
Get Price
Modulating cancer stemness provides luminal a breast
· The stable cell strain OKMS#1 was obtained through concomitantly over-expressing these genes in luminal A breast cancer cells. OKMS#1 cells showed increased invasion proliferation and cancer stemness shared similar drug response pattern with HER2 positive cells and exhibited altered MAPK and enhanced NFkB signaling.
Get Price
Value of Breast Cancer Molecular Subtypes and Ki67
· Luminal A type breast cancer is the most common and least aggressive type with the lowest mortality rate. 33 In addition luminal A mortality rates were reported to be constant over time with mortality rates of luminal B HER2-positive and nonluminal subtypes tending to peak within 5 years after diagnosis which then declined over time 34
Get Price
The invasive lobular carcinoma as a prototype luminal A
· The invasive lobular carcinoma (ILC) known to be the second most common histologic subtype of invasive breast cancer following the invasive ductal carcinoma (IDC) constitutes 8-14 of all breast cancers in most Western reports 1–3 .However in Asia it appears to be very low accounting for only 2-4 in Korea 4–6 and 1-4 in Japan 7 8 .
Get Price
Luminal Breast Cancer Risk of Recurrence and Tumor
· Hormone-receptor positive (HR ) breast cancer (BC) (including the luminal A and the luminal B subtypes) is the most common type of tumor in women diagnosed with early-stage BC (EBC). It represents a highly heterogeneous subgroup that is characterized by different risks of relapse.
Get Price
Modulating cancer stemness provides luminal a breast
· Breast cancer research BCR. 201113 R94 11. Corominas-Faja B Cufi S Oliveras-Ferraros C. et al. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell cycle. 201312 12. Zhao Y Li L Zheng G. et al.
Get PriceLuminal A Breast Cancer and Molecular Assays A Review
· Introduction. Breast cancer is a heterogeneous disease with treatment decisions and prognosis traditionally guided by immunohistochemistry (IHC) markers such as estrogen receptor (ER) progesterone receptor (PR) human epidermal growth receptor 2 (HER2) and Ki67 (a proliferation index marker) along with tumor size tumor grade and nodal status.
Get Price
Luminal A Breast Cancer and Molecular Assays A Review
· Introduction. Breast cancer is a heterogeneous disease with treatment decisions and prognosis traditionally guided by immunohistochemistry (IHC) markers such as estrogen receptor (ER) progesterone receptor (PR) human epidermal growth receptor 2 (HER2) and Ki67 (a proliferation index marker) along with tumor size tumor grade and nodal status.
Get Price
Triggering a switch from basal- to luminal-like breast
· Breast cancer is a heterogeneous disease that includes different molecular subtypes. The basal-like subtype has a poor prognosis and a high recurrence rate whereas the luminal-like subtype
Get Price
Luminal-Type Breast Cancer Correlation of Apparent
· Luminal-type (estrogen receptor–positive) breast cancer is the most frequent subtype (∼70 of cases). Luminal A is defined as a low-proliferation subtype (Ki-67 < 14) and luminal B is defined as a high-proliferation subtype (Ki-67 ≥ 14) as assessed by means of the Ki-67 LI (1–3). Luminal A is not responsive to chemotherapy but is
Get Price
Luminal A and luminal B (HER2 negative) subtypes of breast
· The St Gallen International Expert Consensus 2011 has proposed a new classification system for breast cancer. The purpose of this study was to elucidate the relationship between the breast cancer subtypes determined by the new classification system and genomic characteristics. Invasive breast cancers (n = 363) were immunohistochemically classified as follows 111 (30.6 ) as luminal A
Get Price
Luminal A Breast Canceran overview ScienceDirect Topics
Based on genetic profiling breast cancers are divided into five subtypes luminal A luminal B normal breast–like HER2 and basal-like carcinomas. 34 Luminal A breast cancer is characterized by the high expression of ERs and PRs. These cancers tend to be of a lower grade and have a better prognosis than the other subtypes.
Get Price
Optimal Ki67 cut-off for luminal breast cancer prognostic
· EPIDEMIOLOGY Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation a large case series study with a long-term follow-up Sara Bustreo2 • Simona Osella-Abate1 • Paola Cassoni1 • Michela Donadio2 • Mario Airoldi3 • Fulvia Pedani3 • Mauro Papotti4 • Anna Sapino1 5 • Isabella Castellano1 Received 14 March 2016/Accepted 26 April 2016/Published online 7 May 2016
Get Price
Distinguishing Low-Risk Luminal A Breast Cancer Subtypes
· Low-risk luminal A subtype was defined as negative for both Ki-67 and p53 (luminal A ki-67- p53- ) and others subtypes were considered to be high-risk luminal A breast cancer. A cut-off value of 10 for p53 was a good predictor of clinical outcome in all patients and luminal A breast cancer patients.
Get Price
GATA3 mutations define a unique subtype of luminal‐like
· INTRODUCTION. Breast cancer is the most frequently diagnosed cancer among females accounting for approximately 23 of total cancer cases and approximately 14 of cancer deaths. 1 Clinically this heterogeneous disease is categorized into 4 basic therapeutic groups including luminal A luminal B human epidermal growth factor receptor 2 (HER2)-enriched and basal-like.
Get Price
Luminal A Breast Cancer and Molecular Assays A Review
· Introduction. Breast cancer is a heterogeneous disease with treatment decisions and prognosis traditionally guided by immunohistochemistry (IHC) markers such as estrogen receptor (ER) progesterone receptor (PR) human epidermal growth receptor 2 (HER2) and Ki67 (a proliferation index marker) along with tumor size tumor grade and nodal status.
Get Price
A high-risk luminal A dominant breast cancer subtype with
Purpose Breast cancer is a heterogeneous disease and although advances in molecular subtyping have been achieved in recent years most subtyping strategies target individual genes independent of one another and primarily concentrate on proliferative markers. The contributions of biological processes and immune patterns have been neglected in breast cancer subtype stratification.
Get PriceLuminal A breast carcinoma (Concept Id C)
· A biologic subset of breast carcinoma defined by high expression of genes characteristic of luminal epithelial cells including estrogen receptor (ER) estrogen regulated protein LIV-1 and the transcription factors hepatocyte nuclear factor 3 HNF3A XBP1 and GATA 3. This subtype of breast cancer is associated with a good prognosis.
Get PriceLuminal A Breast Cancer and Molecular Assays A Review
· Introduction. Breast cancer is a heterogeneous disease with treatment decisions and prognosis traditionally guided by immunohistochemistry (IHC) markers such as estrogen receptor (ER) progesterone receptor (PR) human epidermal growth receptor 2 (HER2) and Ki67 (a proliferation index marker) along with tumor size tumor grade and nodal status.
Get Price
Identification of a Low-Risk Luminal A Breast Cancer
· The first large-scale breast cancer gene expression profiling studies classified tumors into four major intrinsic subtypes luminal A luminal B HER2 enriched and basal like. 12 27 Luminal A was the most favorable group with 10-year overall survival rates of approximately 95 and high local relapse-free rates of 92 after breast RT. 17 This
Get Price
Prognostic parameters of luminal A and luminal B intrinsic
· Prognosis of breast cancer and success of therapeutic interventions largely rely on the clinico-pathologic and biological characteristics of the tumor and vary due to the heterogeneous nature of breast cancers. The aim of this study was to determine the frequency and prognostic parameters of luminal breast cancers in our population to devise targeted and personalized therapeutic regimens
Get Price
A high-risk luminal A dominant breast cancer subtype with
Here we identified a high-risk luminal A dominant breast cancer subtype (C3) that displayed increased motility cancer stem cell-like features a higher expression of hormone/luminal-related genes a lower expression of proliferation-related genes and immune dysfunction.
Get Price
The invasive lobular carcinoma as a prototype luminal A
· The invasive lobular carcinoma (ILC) known to be the second most common histologic subtype of invasive breast cancer following the invasive ductal carcinoma (IDC) constitutes 8-14 of all breast cancers in most Western reports 1–3 .However in Asia it appears to be very low accounting for only 2-4 in Korea 4–6 and 1-4 in Japan 7 8 .
Get Price
Identification of a Low-Risk Luminal A Breast Cancer
· The first large-scale breast cancer gene expression profiling studies classified tumors into four major intrinsic subtypes luminal A luminal B HER2 enriched and basal like. 12 27 Luminal A was the most favorable group with 10-year overall survival rates of approximately 95 and high local relapse-free rates of 92 after breast RT. 17 This
Get Price
